Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Review of Medication Therapy for the Prevention of Sickle Cell Crisis.

Literature DB >> 30013299

Review of Medication Therapy for the Prevention of Sickle Cell Crisis.

Tanya R Riley, Angelo Boss, Dominique McClain, Treavor T Riley.

Abstract

This article reviews the clinical data concerning the uses of hydroxyurea, L-glutamine, and crizanlizumab in treating pain crises associated with sickle cell disease.

Entities: Chemical Disease

Year: 2018 PMID： 30013299 PMCID： PMC6027858

Source DB: PubMed Journal: P T ISSN： 1052-1372

27 in total

1. P-selectin mediates the adhesion of sickle erythrocytes to the endothelium.

Authors: N M Matsui; L Borsig; S D Rosen; M Yaghmai; A Varki; S H Embury
Journal: Blood Date: 2001-09-15 Impact factor: 22.113

Review 2. Hydroxyurea for the treatment of sickle cell anemia.

Authors: Orah S Platt
Journal: N Engl J Med Date: 2008-03-27 Impact factor: 91.245

Review 3. Variability of homozygous sickle cell disease: The role of alpha and beta globin chain variation and other factors.

Authors: Graham R Serjeant; Elliott Vichinsky
Journal: Blood Cells Mol Dis Date: 2017-06-21 Impact factor: 3.039

Review 4. Sickle Cell Disease.

Authors: Frédéric B Piel; Martin H Steinberg; David C Rees
Journal: N Engl J Med Date: 2017-04-20 Impact factor: 91.245

Review 5. Hydroxyurea in sickle cell disease: drug review.

Authors: Rohit Kumar Agrawal; Rakesh Kantilal Patel; Varsha Shah; Lalit Nainiwal; Bhadra Trivedi
Journal: Indian J Hematol Blood Transfus Date: 2013-05-24 Impact factor: 0.900

6. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).

Authors: Winfred C Wang; Russell E Ware; Scott T Miller; Rathi V Iyer; James F Casella; Caterina P Minniti; Sohail Rana; Courtney D Thornburg; Zora R Rogers; Ram V Kalpatthi; Julio C Barredo; R Clark Brown; Sharada A Sarnaik; Thomas H Howard; Lynn W Wynn; Abdullah Kutlar; F Daniel Armstrong; Beatrice A Files; Jonathan C Goldsmith; Myron A Waclawiw; Xiangke Huang; Bruce W Thompson
Journal: Lancet Date: 2011-05-14 Impact factor: 79.321

7. Food and Drug Administration Approval of Glutamine for Sickle Cell Disease: Success and Precautions in Glutamine Research.

Authors: Douglas W Wilmore
Journal: JPEN J Parenter Enteral Nutr Date: 2017-08-31 Impact factor: 4.016

8. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.

Authors: Martin H Steinberg; William F McCarthy; Oswaldo Castro; Samir K Ballas; F Danny Armstrong; Wally Smith; Kenneth Ataga; Paul Swerdlow; Abdullah Kutlar; Laura DeCastro; Myron A Waclawiw
Journal: Am J Hematol Date: 2010-06 Impact factor: 10.047

Review 9. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.

Authors: John J Strouse; Sophie Lanzkron; Mary Catherine Beach; Carlton Haywood; Haeseong Park; Catherine Witkop; Renee F Wilson; Eric B Bass; Jodi B Segal
Journal: Pediatrics Date: 2008-12 Impact factor: 7.124

10. L-glutamine therapy reduces endothelial adhesion of sickle red blood cells to human umbilical vein endothelial cells.

Authors: Yutaka Niihara; Neil M Matsui; Yamin M Shen; Dean A Akiyama; Cage S Johnson; M Alenor Sunga; John Magpayo; Stephen H Embury; Vijay K Kalra; Seong Ho Cho; Kouichi R Tanaka
Journal: BMC Blood Disord Date: 2005-07-25

7 in total

Review 1. A Comprehensive Review of the Treatment and Management of Pain in Sickle Cell Disease.

Authors: Jacob Fiocchi; Ivan Urits; Vwaire Orhurhu; Mariam Salisu Orhurhu; Stephen Giacomazzi; Briggs Hoyt; Alan D Kaye; Rachel J Kaye; Omar Viswanath
Journal: Curr Pain Headache Rep Date: 2020-03-21

2. Antisickling Drugs Targeting βCys93 Reduce Iron Oxidation and Oxidative Changes in Sickle Cell Hemoglobin.

Authors: Tigist Kassa; Francine Wood; Michael Brad Strader; Abdu I Alayash
Journal: Front Physiol Date: 2019-07-24 Impact factor: 4.566

3. Ionophore-mediated swelling of erythrocytes as a therapeutic mechanism in sickle cell disease.

Authors: Athena C Geisness; Melissa Azul; Dillon Williams; Hannah Szafraniec; Daniel C De Souza; John M Higgins; David K Wood
Journal: Haematologica Date: 2022-06-01 Impact factor: 11.047

Review 4. Health-Related Quality of Life and Adherence to Hydroxyurea and Other Disease-Modifying Therapies among Individuals with Sickle Cell Disease: A Systematic Review.

Authors: Mira Yang; Lena Elmuti; Sherif M Badawy
Journal: Biomed Res Int Date: 2022-07-18 Impact factor: 3.246

Review 5. Sickle Cell Disease in Children and Adolescents: A Review of the Historical, Clinical, and Public Health Perspective of Sub-Saharan Africa and Beyond.

Authors: Walufu Ivan Egesa; Gloria Nakalema; William M Waibi; Munanura Turyasiima; Emmanuel Amuje; Gloria Kiconco; Simon Odoch; Patrick Kumbowi Kumbakulu; Said Abdirashid; Daniel Asiimwe
Journal: Int J Pediatr Date: 2022-10-08

Review 6. Cell and Gene Therapy for Anemia: Hematopoietic Stem Cells and Gene Editing.

Authors: Dito Anurogo; Nova Yuli Prasetyo Budi; Mai-Huong Thi Ngo; Yen-Hua Huang; Jeanne Adiwinata Pawitan
Journal: Int J Mol Sci Date: 2021-06-10 Impact factor: 5.923

7. Profile of crizanlizumab and its potential in the prevention of pain crises in sickle cell disease: evidence to date.

Authors: Tanya R Riley; Treavor T Riley
Journal: J Blood Med Date: 2019-08-30

7 in total